Affymax (AFFY -63.4%) shares plunge on data that shows safety risks for its anemia drug...

|By:, SA News Editor

Affymax (AFFY -63.4%) shares plunge on data that shows safety risks for its anemia drug Hematide. Non-dialysis patients taking the drug had a higher rate of cardiovascular events, including heart attacks, strokes and death, than those taking Amgen's (AMGN +4.1%) Epogen.